Clinical program

A comprehensive clinical trial program supports the development of MINIject®, with positive combined results at two years from the STAR-I and STAR-II clinical trials shown below. 1

Positive results for MINIject®

Intraocular Pressure (IOP)
  • Meaningful IOP reduction to <15mmHg in most patients
  • ~40% mean IOP reduction after two years
  • Trials designed with stand-alone procedure
  • Nearly half of patients medication-free after two years
  • Medication use reduced by 45% two years post-procedure
  • Significant reduction or elimination of medication side-effects such as eye irritation/burning, eye pain, and skin sensitivity/irritation around the eye ²
Reduced complications
  • Low re-intervention rate up to two years
  • Bleb-free and conjunctiva sparing procedure - no needling, no MMC required
  • Very low number of patients with >30% central endothelial cell density (ECD) loss at two years



Evidence-based data on safety and efficacy

  • More than 150 patients in clinical trials
  • 11 trial centers throughout Europe, India and Latin America
  • MINIject assessed as stand-alone procedure – no enhancement of outcomes from joint cataract surgery
  • Published results after two-years of follow-up



1 Data on file and presented by CEO Michel Vanbrabant at Ophthalmology Innovation Summits (OIS) in 2021.

2 Denis P, Hirneiß C, Durr GM, et al. “Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial”. Br J Ophthalmol 2020;0:1–6

3 García Feijoó J, Denis P, Hirneiß C et al. “A European Study of the Performance and Safety of MINIjectTM in Patients With Medically Uncontrolled Open-angle Glaucoma (STAR-II)”. J Glaucoma. 2020 Oct;29(10):864-871





scroll to up
Sign up to receive company news alerts